Drugmaker Pfizer Inc. is under investigation by state attorneys general from New York and Connecticut in connection with improper promotion of drugs for uses other than those approved by U.S. regulators, Pfizer said in a regulatory filing.
The drugmaker also said it has initiated an internal probe relating to its sales operations in Croatia.
In the New York investigation, Pfizer said it has received a letter from Attorney General Eliot Spitzer's office requesting documents and information on clinical trials of certain drugs for uses other than those approved by the U.S. Food and Drug Administration. Pfizer said the probe involved the possible promotion of products for unapproved uses.
Pfizer said it received a letter from the Office of the Attorney General of the State of Connecticut requesting similar materials concerning Zoloft.
Pfizer spokesman Paul Fitzhenry said both investigations were new, but declined to specify which drugs the New York attorney general was investigating. A spokesman for Spitzer's office declined to comment.
Pfizer also said it has voluntarily provided the Department of Justice and the Securities and Exchange Commission with information regarding an internal probe of certain potentially improper payments made in connection with foreign sales activities in Croatia.
The Pfizer spokesman declined to comment on the investigation.